2. Anti-infection Apoptosis
  3. Fungal Apoptosis
  4. Lawsone

Lawsone  (Synonyms: 2-羟基-1,4-萘醌)

目录号: HY-N2493 纯度: 99.36%
COA 产品使用指南

摩尔计算器

Lawsone 是一种具有口服活性的萘醌染料，可从 Lawsonia inermis 的叶片中分离得到。Lawsone 可诱导细胞凋亡 (apoptosis)。Lawsone 有抗菌、抗肿瘤和抗氧化活性。Lawsone 可用于抗肿瘤药物研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Lawsone Chemical Structure

Lawsone Chemical Structure

CAS No. : 83-72-7

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ￥610
In-stock
500 mg ￥550
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Lawsone:

Lawsone 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 1 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research[1][2][3][4][5].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
58 μM
Compound: 17
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
[PMID: 24374273]
HeLa IC50
> 100 μM
Compound: 1c
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24913712]
Hepatocyte CC50
> 500 μM
Compound: Lawsone
Cytotoxicity activity against Swiss Webster mouse primary hepatocytes assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
Cytotoxicity activity against Swiss Webster mouse primary hepatocytes assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
[PMID: 29289882]
HFF-1 IC50
> 50 μM
Compound: 7
Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
[PMID: 34438124]
Hs 683 IC50
31 μM
Compound: 17
Growth inhibition of human Hs683 cells by MTT assay
Growth inhibition of human Hs683 cells by MTT assay
[PMID: 24374273]
LoVo IC50
> 100 μM
Compound: 17
Growth inhibition of human LoVo cells by MTT assay
Growth inhibition of human LoVo cells by MTT assay
[PMID: 24374273]
MCF7 IC50
> 50 μM
Compound: 1
Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
[PMID: 31810778]
MDA-MB-231 IC50
> 50 μM
Compound: 1
Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
[PMID: 31810778]
PC-3 IC50
> 100 μM
Compound: 17
Growth inhibition of human PC3 cells by MTT assay
Growth inhibition of human PC3 cells by MTT assay
[PMID: 24374273]
SAS IC50
> 100 μM
Compound: 1c
Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24913712]
SK-BR-3 IC50
> 50 μM
Compound: 1
Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay
[PMID: 31810778]
SK-MEL-28 IC50
> 100 μM
Compound: 17
Growth inhibition of human SK-MEL-28 cells by MTT assay
Growth inhibition of human SK-MEL-28 cells by MTT assay
[PMID: 24374273]
U-373MG ATCC IC50
> 100 μM
Compound: 17
Growth inhibition of human U373 cells by MTT assay
Growth inhibition of human U373 cells by MTT assay
[PMID: 24374273]
Vero CC50
213.74 μM
Compound: Lawsone
Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay
[PMID: 29289882]
体外研究
(In Vitro)

Lawsone (125, 250, 500 μM, 18 h) 剂量依赖性的抑制大肠杆菌的生长[3]。
Lawsone (0.5, 1, 1.5, 2 mg/mL, 48 h) 在人 DLD-1 细胞中通过降低 NF-κB 活性导致细胞周期蛋白 B1 和 cdk1 的表达水平受到抑制而抑制细胞增殖[4]。
Lawsone (10, 20, 40, 80, 160 mg/mL, 24 h) 在 SKOV-3 卵巢癌细胞中具有抗增殖作用，通过抑制 Bcl-2 诱导细胞凋亡[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Lawsone 相关抗体:

Cell Proliferation Assay[4]

Cell Line: DLD-1, MRC-5
Concentration: 0.5, 1, 1.5, 2 mg/mL
Incubation Time: 24-96 h
Result: Demonstrated significant suppression at concentration 2 mg/ml on DLD-1 cells and exhibited no suppression on normal fibroblast MRC-5 cells.

Western Blot Analysis[4]

Cell Line: DLD-1
Concentration: 0.5, 1, 1.5, 2 mg/mL
Incubation Time: 48 h
Result: Decreased the level of both proteins cyclin B1 and cdk1.
Exhibited a dose-dependent effect on translocation of p65 of cytosol to the nucleus.
体内研究
(In Vivo)

Lawsone (62.5, 125, 250, 500, 750 μmol/kg/day, 口服) 在大鼠中可诱导与红细胞氧化损伤相关的溶血反应[2]。
Lawsone (200 mg/mL, 口服, 持续 8 周) 对大鼠结肠癌有明显的抑制作用[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female rat model (10-11- week-old)[2]
Dosage: 62.5, 125, 250, 500, 750 μmol/kg/day
Administration: p.o.
Result: Increased the levels of ALT, AST, GLDH, LDH, HBDH, urea and creatinine at a dose of 500 or 750 μmol/kg/day.
Animal Model: Rat model of colon cancer[4]
Dosage: 200 mg/mL
Administration: p.o.
Result: Reduced the tumor diameters and decreased multiplicity of these adenomas.
Decreased the PCNA staining index
分子量

174.16

Formula

C10H6O3
CAS 号
性状

固体

颜色

Light yellow to yellow

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶解性数据
细胞实验： 

DMSO 中的溶解度 : 100 mg/mL (574.20 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 5.7420 mL 28.7101 mL 57.4201 mL
5 mM 1.1484 mL 5.7420 mL 11.4840 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (14.36 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (14.36 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

    2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.36%

COA (288 KB) HNMR (127 KB) RP-HPLC (221 KB)

产品使用指南 (1538 KB)
参考文献

Lawsone 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 5.7420 mL 28.7101 mL 57.4201 mL 143.5503 mL
5 mM 1.1484 mL 5.7420 mL 11.4840 mL 28.7101 mL
10 mM 0.5742 mL 2.8710 mL 5.7420 mL 14.3550 mL
15 mM 0.3828 mL 1.9140 mL 3.8280 mL 9.5700 mL
20 mM 0.2871 mL 1.4355 mL 2.8710 mL 7.1775 mL
25 mM 0.2297 mL 1.1484 mL 2.2968 mL 5.7420 mL
30 mM 0.1914 mL 0.9570 mL 1.9140 mL 4.7850 mL
40 mM 0.1436 mL 0.7178 mL 1.4355 mL 3.5888 mL
50 mM 0.1148 mL 0.5742 mL 1.1484 mL 2.8710 mL
60 mM 0.0957 mL 0.4785 mL 0.9570 mL 2.3925 mL
80 mM 0.0718 mL 0.3589 mL 0.7178 mL 1.7944 mL
100 mM 0.0574 mL 0.2871 mL 0.5742 mL 1.4355 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lawsone83-72-7FungalApoptosisAntitumorDLD-1SKOV-3Colon cancer rat modelInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Lawsone
目录号：
HY-N2493
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z